Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| MENTOR GRAPH | MENT | 2.70% |
| INFORMATION | III | 2.62% |
| GENTIUM SPA | GENT | 2.47% |
| VIPSHOP HOLD | VIPS | 2.24% |
| AMER NATL BK | AMNB | 1.99% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Food packaging maker Landec Corp. (LNDC - Snapshot Report) has an impressive streak of positive quarterly earnings surprises, which it continued earlier this month with a nearly 44% beat in its fiscal second quarter. Meanwhile, the stock price rocketed roughly 61% last year.
Given its flurry of earnings beats, double-digit earnings growth projections, healthy growth in the fresh-cut produce category, continued product innovation and synergies from an acquisition, this Zacks Rank #1 (Strong Buy) deserves some attention from aggressive growth investors.
Seventh Straight Beat
On January 2, Landec reported a positive earnings surprise of 43.75% for its fiscal second quarter. Adjusted earnings of 23 cents per share comfortably beat the Zacks Consensus Estimate of 16 cents, marking the seventh consecutive positive surprise.
Revenues surged 41% year over year to $114.7 million, driven by a strong performance from the companys fresh-cut specialty packaged food subsidiary Apio, Inc.'s value-added business. GreenLine Holding Company, which was acquired by Apio in April 2012, contributed $24.3 million in revenues. Landec said that GreenLine integration is progressing well and is ahead of its original plan.
By business lines, total revenues from Apio shot up 50% year over year to $106.7 million, boosted by new products and gains in the fresh-cut vegetable category. However, revenues from Lifecore Biomedical, the companys biomaterials unit, slipped 16% to $7.7 million due to a delay in shipment and the termination of its licensing agreement with Monsanto Company (MON).
The company raised its revenues and profit growth forecasts for fiscal 2013. It now expects revenues to rise 33% to 38% year over year, compared with its earlier forecast of 30%. Moreover, it sees net income growth of 60% to 70%, up from its prior projection of 25% to 35%.
Earnings Estimates Moving Higher
Two out of three estimates have moved higher for both fiscal 2013 and fiscal 2014 over the last 7 days. As a result, the Zacks Consensus Estimate for fiscal 2013 has gained 12% to 73 cents per share, indicating an estimated annualized increase of roughly 50%.
For fiscal 2014, the Zacks Consensus Estimate rose 4% in 7 days to 88 cents per share, representing a projected year over year rise of nearly 20%.
Reasonable Valuation
Landec is currently trading at a forward P/E of 16.45x, which is higher than the peer group average of 14.85x. The price-to-book of 1.97x and the price-to-sales (P/S) ratio of 0.82 are also higher than their peer group averages. However, the premium valuation is justified given the healthy earnings trajectory.
The stock has begun to catch up with the rising earnings estimates of late, signaling the potential for further upside.
Landec Corporation makes and distributes polymer products using its proprietary polymer technologies for food and biomaterials markets. The companys Apio unit is a leading provider of fresh-cut specialty packaged vegetables in North America. Its Lifecore subsidiary is a premium supplier of hyaluronan-based materials and medical products for ophthalmic, orthopedic, veterinary and other medical applications. Landec, which has a market cap of roughly $311 million, distributes its products leveraging its dedicated sales and marketing resources globally.
Want More of Our Best Recommendations?
Zacks' Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Then each week he hand-selects the most compelling trades and serves them up to you in a new program called Zacks Confidential.
Learn More>>
Read the full reports :
Snapshot Report on LNDC